Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.72 |
| ▸ | MCL1 | Q07820 | 14/20 | 0.63 |
| ▸ | ALB | P02768 | 1/20 | 0.56 |
| ▸ | BCL2 | P10415 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL223344 | 1.00 | FOLH1 (1.00) | FOLH1KDM4EALDH1A1MCL1ALB | |
| SCHEMBL5955774 | 0.85 | ALDH1A1 (0.74) | FOLH1KDM4EALDH1A1MCL1ALB | |
| SCHEMBL29432490 | 0.84 | KDM4E (1.00) | FOLH1KDM4EALDH1A1MCL1 | |
| SCHEMBL2003146 | 0.84 | KDM4E (0.72) | FOLH1KDM4EALDH1A1MCL1ALB | |
| SCHEMBL9188195 | 0.84 | KDM4E (1.00) | FOLH1KDM4EALDH1A1MCL1 | |
| SCHEMBL2002751 | 0.83 | FOLH1 (0.71) | FOLH1KDM4EALDH1A1MCL1ALB | |
| SCHEMBL13701155 | 0.83 | KDM4E (0.71) | FOLH1KDM4EALDH1A1MCL1ALB | |
| SCHEMBL3205801 | 0.81 | KDM4E (0.69) | FOLH1KDM4EALDH1A1MCL1ALB | |
| SCHEMBL29621784 | 0.81 | KDM4E (0.69) | FOLH1KDM4EALDH1A1MCL1ALB | |
| SCHEMBL5971268 | 0.81 | KDM4E (0.68) | FOLH1KDM4EALDH1A1MCL1ALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025238236-A1 | POLYPLEXES OF NUCLEIC ACIDS AND TARGETED CONJUGATES COMPRISING POLYETHYLENEIMINE AND POLYETHYLENE GLYCOL | TARGIMMUNE THERAPEUTICS AG (CH) | 2025-11-20 | — | — | WO | disclosed |
| EP-4615511-A1 | TARGETED LINEAR CONJUGATES COMPRISING POLYETHYLENEIMINE AND POLYETHYLENE GLYCOL AND POLYPLEXES COMPRISING THE SAME | TargImmune Therapeutics AG (CH) | 2025-09-17 | — | — | EP | disclosed |
| EP-4615509-A1 | PSMA-TARGETING LINEAR CONJUGATES COMPRISING POLYETHYLENEIMINE AND POLYETHYLENE GLYCOL AND POLYPLEXES COMPRISING THE SAME | TargImmune Therapeutics AG (CH) | 2025-09-17 | — | — | EP | disclosed |
| EP-4615510-A1 | POLYPLEXES OF NUCLEIC ACIDS AND TARGETED CONJUGATES COMPRISING POLYETHYLENEIMINE AND POLYETHYLENE GLYCOL | TargImmune Therapeutics AG (CH) | 2025-09-17 | — | — | EP | disclosed |
| EP-4426358-A2 | TARGETED LINEAR CONJUGATES COMPRISING POLYETHYLENEIMINE AND POLYETHYLENE GLYCOL AND POLYPLEXES COMPRISING THE SAME | TargImmune Therapeutics AG (CH) | 2024-09-11 | — | — | EP | disclosed |
| CN-118510547-A | Targeted linear conjugates comprising polyethylenimine and polyethylene glycol and polymer complexes comprising the same | 塔尔格免疫治疗有限公司 | 2024-08-16 | — | — | CN | disclosed |
| WO-2024100040-A1 | PSMA-TARGETING LINEAR CONJUGATES COMPRISING POLYETHYLENEIMINE AND POLYETHYLENE GLYCOL AND POLYPLEXES COMPRISING THE SAME | TARGIMMUNE THERAPEUTICS AG (CH) | 2024-05-16 | — | — | WO | disclosed |
| WO-2024100046-A1 | TARGETED LINEAR CONJUGATES COMPRISING POLYETHYLENEIMINE AND POLYETHYLENE GLYCOL AND POLYPLEXES COMPRISING THE SAME | TARGIMMUNE THERAPEUTICS AG (CH) | 2024-05-16 | — | — | WO | disclosed |
| WO-2024100044-A1 | POLYPLEXES OF NUCLEIC ACIDS AND TARGETED CONJUGATES COMPRISING POLYETHYLENEIMINE AND POLYETHYLENE GLYCOL | TARGIMMUNE THERAPEUTICS AG (CH) | 2024-05-16 | — | — | WO | disclosed |
| EP-4351520-A1 | NOVEL PARTICLE COMPOSITION COMPRISING SIALIC ACID BINDING LIGAND | CYTODIGM, INC. (US) | 2024-04-17 | — | — | EP | disclosed |
| CN-117750946-A | Novel particulate compositions comprising sialic acid binding ligands | 希托迪格姆公司 | 2024-03-22 | — | — | CN | disclosed |
| EP-4225374-A1 | IMMUNOTHERAPY FOR THE TREATMENT OF CANCER | TargImmune Therapeutics AG (CH) | 2023-08-16 | — | — | EP | disclosed |
| CN-116568331-A | Pharmaceutical compositions of SIGLEC-binders | 希托迪格姆公司 | 2023-08-08 | — | — | CN | disclosed |
| CN-116348142-A | Immunotherapy for the treatment of cancer | 塔尔格免疫治疗有限公司 | 2023-06-27 | — | — | CN | disclosed |
| WO-2023079142-A2 | TARGETED LINEAR CONJUGATES COMPRISING POLYETHYLENEIMINE AND POLYETHYLENE GLYCOL AND POLYPLEXES COMPRISING THE SAME | TARGIMMUNE THERAPEUTICS AG (CH) | 2023-05-11 | — | — | WO | disclosed |
| WO-2022261207-A1 | NOVEL PARTICLE COMPOSITION COMPRISING SIALIC ACID BINDING LIGAND | CYTODIGM, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
| WO-2022074152-A1 | IMMUNOTHERAPY FOR THE TREATMENT OF CANCER | TARGIMMUNE THERAPEUTICS AG (CH) | 2022-04-14 | — | — | WO | disclosed |
| CN-114072130-A | Microparticles and nanoparticles having sulfate groups on the surface | 法斯瑞斯公司 | 2022-02-18 | — | — | CN | disclosed |